Bilharzia (schistosomiasis) - Symptoms, Causes, Treatment & Prevention

Overview

Bilharzia, more commonly known as schistosomiasis, is a parasitic disease caused by flatworms (trematodes) of the genus Schistosoma. The adult worms live in the blood vessels of the host and release eggs that can become lodged in tissues, provoking inflammation and damage.

The disease is endemic in tropical and subtropical regions, especially in sub‑Saharan Africa, parts of the Middle East, South America, and Southeast Asia. According to the World Health Organization (WHO), an estimated 240 million people are infected worldwide, with over 700 million at risk of exposure.

Schistosomiasis primarily affects people who have regular contact with freshwater sources that contain the infectious larval stage (cercariae). It is a leading cause of chronic morbidity in low‑ and middle‑income countries and can impair growth, cognitive development, and economic productivity.

Symptoms

The clinical picture varies by species, infection intensity, and duration. Symptoms are often grouped into three phases:

1. Acute (Cercarial Dermatitis or “Swimmer’s Itch”)

• Skin rash at the site of penetration – red papules that become itchy or painful within minutes to days.
• Fever, chills, and malaise – systemic reaction to migrating larvae.
• Muscle aches and headache.

2. Katayama Fever (Early‑stage systemic reaction, weeks after exposure)

• High fever (often >38.5 °C)
• Dry cough, chest tightness
• Abdominal pain, diarrhea (sometimes bloody)
• Hepatosplenomegaly (enlarged liver and spleen)
• Eosinophilia – markedly elevated eosinophils in blood tests.

3. Chronic Schistosomiasis (Months to years after infection)

• Genitourinary involvement (S. haematobium)
  • Hematuria (blood in urine) – often the first sign.
  • Dysuria, frequency, urgency.
  • Bladder wall thickening, fibrosis, and increased risk of squamous cell carcinoma.
  • In men, seminal vesicle involvement causing painful ejaculation or infertility.
• Intestinal involvement (S. mansoni, S. japonicum, S. intercalatum)
  • Abdominal pain, cramping, and colicky diarrhoea.
  • Blood or mucus in the stool.
  • Intestinal ulceration and polyps.
  • Growth retardation in children.
• Hepatosplenic disease (often S. mansoni, S. japonicum)
  • Portal hypertension → ascites, variceal bleeding.
  • Fibrosis of the liver and peri‑portal “pipestem” fibrosis.
  • Splenomegaly, anemia, and thrombocytopenia.
• Neurologic involvement (rare, but serious)
  • Spinal cord or brain granulomas – causing seizures, paresis, or paraplegia.
• Other systemic signs
  • Chronic fatigue, malaise.
  • Weight loss, anemia.
  • Elevated IgE levels.

Causes and Risk Factors

Life Cycle Overview

Understanding the parasite’s life cycle clarifies why certain behaviors increase risk:

1. Eggs released in urine (S. haematobium) or feces (other species) reach freshwater.
2. In water, eggs hatch into miracidia, which infect specific freshwater snails (intermediate hosts).
3. Inside snails, they develop into cercariae, the free‑swimming larval form.
4. Humans become infected when cercariae penetrate intact skin during water contact.
5. Larvae migrate through the circulatory system, mature into adult worms (male–female pairs), and lodge in veins of the bladder, intestines, or liver.
6. Adults lay eggs; some are expelled, while others become trapped, causing inflammation.

Key Risk Factors

• Geographic exposure – Living in, traveling to, or working in endemic regions.
• Occupational activities – Fishermen, rice‑farm workers, irrigation engineers, and soldiers who wade in fresh water.
• Recreational water contact – Swimming, bathing, or playing in contaminated lakes or rivers.
• Poor sanitation – Open defecation or lack of latrines that facilitate egg contamination of water.
• Age – Children often have higher infection rates due to play in water.
• Immunocompromised status – May lead to more severe disease.

Diagnosis

Accurate diagnosis combines clinical suspicion with laboratory and imaging tools.

Laboratory Tests

• Stool microscopy – The Kato‑Katz technique quantifies eggs of intestinal species. Sensitivity improves with multiple samples (3‑5 days).
• Urine filtration – Detects S. haematobium eggs; best performed between 10 am–2 pm when egg excretion peaks.
• Serology – Antibody detection (ELISA, indirect hemagglutination) useful for travelers or low‑intensity infections, but cannot distinguish active from past infection.
• Circulating cathodic antigen (CCA) test – A rapid urine dipstick for S. mansoni; high sensitivity in endemic settings.
• Eosinophil count – Frequently elevated (>500 cells/µL) during acute infection.

Imaging

• Ultrasound – Evaluates liver, spleen, and bladder wall thickness; WHO grading system monitors morbidity.
• CT/MRI – Reserved for suspected CNS involvement or complex organ disease.

Other Diagnostic Considerations

In migrants or immigrants, a single negative stool/urine test does not exclude infection; repeat testing or serology may be required. In pregnancy, urine filtration remains safe; stool and serology are also acceptable.

Treatment Options

Antiparasitic Medication

The drug of choice worldwide is praziquantel.

• Typical dose: 40 mg/kg orally in a single day (often split into two doses of 20 mg/kg 4–6 hours apart).
• Effectiveness: >90 % cure rate for most species; may require repeat dosing for heavy infections.
• Safety: Generally well tolerated; mild nausea, abdominal discomfort, or dizziness may occur.

For S. japonicum infections in some regions, a higher total dose (60 mg/kg) is recommended.

Adjunctive Therapy

• Antibiotics (e.g., doxycycline) have experimental use in reducing snail populations but are not standard for human infection.
• Corticosteroids may be indicated in severe CNS disease to reduce inflammatory edema.
• Iron supplementation for anemia and nutritional support in chronic disease.

Lifestyle & Supportive Measures

• Hydration and balanced diet to support recovery.
• Management of bladder symptoms with urinary analgesics or anticholinergics if needed.
• Regular follow‑up ultrasounds for hepatosplenic disease.

Living with Bilharzia (schistosomiasis)

Even after successful treatment, many patients experience residual organ changes. The following strategies help maintain health and prevent re‑infection.

Medical Follow‑up

• Repeat stool/urine testing 4–6 weeks post‑treatment to confirm cure.
• Annual ultrasound for those with prior hepatosplenic involvement.

Symptom Management

• Address hematuria or urinary urgency with pelvic floor exercises and, if necessary, urologist referral.
• Use fiber‑rich diet and adequate fluids to prevent constipation from intestinal disease.
• Consult a mental‑health professional if chronic fatigue or depression develops.

Community & Social Support

• Participate in local de‑worming campaigns; many endemic countries provide mass‑drug administration (MDA) annually.
• Engage school‑based health education programs to reduce exposure among children.

Prevention

Prevention combines personal protection, environmental control, and public‑health measures.

Personal Protective Measures

• Avoid swimming, wading, or washing in freshwater bodies known or suspected to be contaminated.
• If contact is unavoidable, wear water‑proof boots and gloves and consider applying a barrier cream containing repellents (e.g., DEET) that may deter cercariae.
• Use safe, treated water for drinking, cooking, and personal hygiene.

Community‑Level Interventions

• Snail control – Application of molluscicides (niclosamide) and environmental modification (drainage, lining canals).
• Improved sanitation – Building latrines, safe sewage disposal, and health education to stop egg contamination of water.
• Mass drug administration (MDA) – WHO recommends annual praziquantel distribution to at‑risk populations (especially school‑aged children).

Vaccines & Research

As of 2024, no commercially available vaccine exists, but several candidates are in Phase II trials. Keeping informed about clinical trial opportunities may be relevant for endemic‑region residents.

Complications

If left untreated or inadequately treated, schistosomiasis can lead to severe, sometimes irreversible, health problems.

• Genitourinary cancer – Chronic S. haematobium infection is classified by WHO as a Group 1 carcinogen for bladder cancer.
• Portal hypertension – Leads to variceal bleeding, ascites, and liver failure.
• Splenic sequestration – Massive splenomegaly, anemia, thrombocytopenia.
• Neurologic disease – Spinal cord myelopathy, cerebral granulomas, seizures.
• Growth retardation & cognitive impairment in children, affecting school performance.
• Infertility – Due to uterine or testicular fibrosis.
• Secondary bacterial infections – From ulcerated lesions in the bladder or intestines.

When to Seek Emergency Care

References

• World Health Organization. Schistosomiasis Fact Sheet. 2023.
• CDC. Parasitic Diseases: Schistosomiasis. Updated 2024.
• Mayo Clinic. Schistosomiasis (Bilharzia). 2024 review.
• Cleveland Clinic. Schistosomiasis: Symptoms, Diagnosis, Treatment. 2023.
• Hotez PJ, et al. “Schistosomiasis.” The Lancet. 2022;399:1255‑1268.
• Neglected Tropical Diseases Collaboration. “WHO Guidelines for the Prevention and Control of Schistosomiasis.” 2022.